Eurofarma and Dentsu Creative have teamed up to launch a new app that allows people with Parkinson’s disease to engage with social media by changing their facial expressions. The app’s goal is to give patients a fun and easy way to exercise their facial muscles. The idea…
Gain Therapeutics has been awarded about $2.8 million to advance the development of GT-02287, its lead therapeutic candidate for GBA1-associated Parkinson’s disease. Innosuisse, the Swiss Innovation Agency, granted the 2.5 million Swiss francs to the company under its Swiss Accelerator program, which provides funding for new…
h2o Therapeutics has partnered with AmerisourceBergen to commercialize Parky, a prescription mobile app that monitors symptoms in people with Parkinson’s disease, such as tremors and involuntary muscle movements. The Parky app monitors a patients’ symptoms in real time using an Apple Watch, and shares the data…
NeuroOne Medical Technologies‘ Evo stereoelectroencephalography (sEEG) electrodes for measuring or stimulating brain activity in people with neurological diseases like Parkinson’s disease or epilepsy are now available commercially in the U.S. The electrodes were approved by the U.S. Food and Drug Administration (FDA) in October for less than…
People newly diagnosed with Parkinson’s disease were found to have significantly lower blood levels of the argonaute 2 (AGO2) protein relative to healthy adults, according to a recent biomarker study conducted by NeuroSense Therapeutics. In people with amyotrophic lateral sclerosis (ALS), the company’s PrimeC treatment candidate previously…
PharmaTher Holdings has applied to the U.S. Food and Drug Administration (FDA) asking that ketamine be given fast-track designation as a potential treatment for dyskinesia, or uncontrolled movements, that occur as a side effect of levodopa being used by people with Parkinson’s disease. The fast-track designation is designed…
A once-daily 200 mg dose of IkT-148009, Inhibikase Therapeutics‘ investigational therapy for Parkinson’s disease, reached steady levels in the body after four days without causing any serious side effects in healthy volunteers. The company plans to include this dose in its ongoing Phase 2 study (NCT05424276) in…
Abbvie is funding a clinical trial called PROSPECT to assess how clinical outcomes and disease burden change over time for people with Parkinson’s disease whose symptoms are not adequately controlled with available treatments. Interim data from the trial, presented at this year’s American Academy of Neurology (AAN) annual…
An assay using skin biopsies, called the Syn-One Test, was able to detect the alpha-synuclein protein that characterizes Parkinson’s disease and like conditions in more than 90% of the patients enrolled in a clinical trial. “These results validate cutaneous [skin-based] alpha-synuclein as a reliable biomarker for Parkinson’s disease and…
Noninvasive low-intensity focused ultrasound (LIFU) temporarily opened the blood-brain barrier to allow molecules to enter the brains of Parkinson’s disease patients, a study reports. In nonhuman primates, LIFU safely enhanced the delivery of a gene therapy model using a harmless, modified virus directly to the striatum, a region affected…
Get regular updates to your inbox.
